Targeted KRAS TCR-T cell therapy(Immuxell Biotech)

N/A

Report date: 2024/07/10 17:52:43

Base Information

Drug NameTargeted KRAS TCR-T cell therapy(Immuxell Biotech)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionT lymphocyte replacementsV-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog modulators
TargetsGTPase KRas
Therapy Area/IndicationsCarcinoma, Pancreatic Ductal
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaClinical
Originator CompaniesShanghai Immuxell Biotech Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Immuxell Biotech Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Pancreatic Ductal
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A